Open Access Open Access  Restricted Access Subscription or Fee Access

Medical Research: What Is Wrong with this Picture?

Vance W Berger, Kaitlin Elizabeth Palys

Abstract


Abstract:

There is a fundamental disconnect between the perception and the reality of the rigor and validity of medical research.  The basic flaws that run rampant in the design and analysis of clinical trials belie the commonly held view that clinical trials are beyond reproach by virtue of occupying the top level of evidence-based medicine.  This fact has been amply demonstrated in the literature, and, for the most part, ignored by those who continue to praise the virtues of randomized evidence, without qualification.  When a machine produces too many broken widgets, it becomes clear that it is the machine itself, and not just the widgets, that require attention.  The machine that produces medical research is broken, and needs our collective attention.  We will frame some of the problems with medical research in terms of moral hazard, unfunded mandates, conflicts of interest, and incentives.  These perspectives will give rise to suggestions that, if adopted, would reduce the conflicts, and could also go on to greatly improve the integrity of medical research, which in turn would improve the overall quality of medical care.


Keywords


Conflict of Interest; Conflicted Researcher; Funding Source; Incentives; Moral Hazard; Public Trust; Research Malpractice; Unfunded Mandate

Full Text:

PDF

References


References

Altman DG, The Scandal of Poor Medical Research, British Medical Journal 1994;308:283-284.

Berger, VW, Ioannidis, JPA, The Decameron of Poor Research, British Medical Journal 2004;329:1436-1440.

Berger, VW, Selection Bias and Covariate Imbalances in Randomized Clinical Trials, John Wiley and Sons, Chichester, 2005.

Berger, VW, Matthews, JR, Grosch, EN, On Improving Research Methodology in Clinical Trials, Statistical Methods in Medical Research 2008;17:231-242.

Berger, VW, Matthews, JR, Conducting Today’s Trials by Tomorrow’s Standards, Pharmaceutical Statistics 2005;4:155-159.

Lipsey, RG, Steiner, PO, Purvis, DD, and Courant, PN. “Microeconomics”, Harper and Row, New York, 1990.

Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S, Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics, The American Journal of Psychiatry 2006;163(2):185-194.

Angell, M, The Truth about the Drug Companies: How They Deceive Us and What To Do about It, Random House, New York, 2005.

Meade MO, Cook DJ, Guyatt GH, et al. Ventilation strategy using low tidal volumes , recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008 Feb 13;299(6):637-45.

Berger, VW, Matthews, JR, Grosch, EN, On Improving Research Methodology in Clinical Trials, Statistical Methods in Medical Research 2008;17:231-242.

Berger, VW, Rezvani, A, Makarewicz, V, Direct Effect on Validity of Response Run-in Selection in Clinical Trials, Controlled Clinical Trials 2003;24(2):156-166.

Berger, VW, Bears, J, When Can a Clinical Trial Be Called ‘Randomized’?, Vaccine 2003;21:468-472.

O'Riordan, M (2009). "Mistakes" Made: FDA Acknowledges Lilly Phoned To Question Sanjay Kaul's Inclusion on Prasugrel Panel. theheart.org. [Clinical Conditions > Acute Coronary Syndrome > Acute coronary syndromes]; Feb 20, 2009. Accessed at http://www.theheart.org/article/943511.do on Feb 23, 2009.

Packer, M, Bristow, MR, Cohn, JN, et al., The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure, New England Journal of Medicine 1996;334(21):1349-1355.

Von Olshausen, K, Pop, T, Berger, J, Letter to the Editor, New England Journal of Medicine 1996;335(17):1319-1320.

Moye, LA, Letter to the Editor, New England Journal of Medicine 1996;335(17):1318.

Moye, LA, End-Point Interpretation in Clinical Trials: The Case for Discipline, Controlled Clinical Trials 1999;20:40-49.

Fauchier, L, Pierre, B, de Labriolle, A, Babuty, D, Comparison of the Beneficial Effect of Beta-Blockers on Mortality in Patients with Ischemic or Non-Ischemic Systolic Heart Failure: A Meta-Analysis of Randomized Controlled Trials, European Journal of Heart Failure 2007;9:1136-1139.

Jureidini, JN, McHenry, LB, and Mansfield, PR, Clinical Trials and Drug Promotion: Selective Reporting of Study 329, International Journal of Risk & Safety in Medicine 2008;20:73-81.

Keller, MB, Ryan, ND, Strober, M, Klein, RG, Kutcher, SP, Birmaher, B, et al, Efficacy of Paroxetine in the Treatment of Adolescent Depression: A Randomized, Controlled Trial, Journal of the American Academy of Child and Adolescent Psychiatry 2001;40:762-772.

Lachin JM, Worst-rank Score Analysis with Informatively Missing Observations in Clinical Trials, Controlled Clinical Trials 1999;20:408-422.

Lovell, DJ, Giannini, EH, Reiff, A, et al., Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis, New England Journal of Medicine 2000;342:763-769.

Berger, VW (1999). FDA Product Approval Information – Licencing Action: Statistical Review. Http://www.fda.gov/cder/biologics/review/etanimm052799r2.pdf (accessed February 28, 2005).

Berger, VW, The p-value Interval as an Inferential Tool, Journal of the Royal Statistical Society D (The Statistician) 2001;50(1):79-85.

Berger, VW, On the Generation and Ownership of Alpha in Medical Studies, Controlled Clinical Trials 2004;25(6):613-619.

Smith, R, Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies, PLOS Medicine 2005;2(5):E138




DOI: http://dx.doi.org/10.5750/ijpcm.v2i4.241

Refbacks

  • There are currently no refbacks.